Inherited thrombophilia

被引:52
作者
Franchini, Massimo
Veneri, Dino
Salvagno, Gian Luca
Manzato, Franco
Lippi, Giuseppe
机构
[1] Azienda Osped Verona, Serv Immunoematol & Trasfuz, I-37134 Verona, Italy
[2] Univ Verona, Div Ematol, Dipartimento Med Sperimentale & Clin, I-37100 Verona, Italy
[3] Univ Verona, Ist Chim & Microscopia Clin, Dipartimento Sci Biomed & Morfol, I-37100 Verona, Italy
[4] Osped C Poma, Lab Anal Chim Clin, Mantua, Italy
关键词
coagulation; inherited thrombophilia; prothrombotic gene mutations; venous thrombosis; arterial thrombosis; genetics; childhood; pregnancy; anticoagulation; therapy;
D O I
10.1080/10408360600552678
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Inherited thrombophilia can be defined as a genetically determined predisposition to the development of thromboembolic complications. Since the discovery of activated protein C resistance in 1993, several additional disorders have been described and, at present, it is possible to identify an inherited predisposition in about 60 to 70% of patients with such complications. These inherited prothrombotic risk factors include qualitative or quantitative defects of coagulation factor inhibitors, increased levels or function of coagulation factors, defects of the fibrinolytic system, altered platelet function, and hyperhomocysteinemia. In this review, the main inherited prothrombotic risk factors are analyzed from epidemiological, laboratory, clinical, and therapeutic points of view. Finally, we discuss the synergism between genetic and acquired prothrombotic risk factors in particular conditions such as childhood and pregnancy.
引用
收藏
页码:249 / 290
页数:42
相关论文
共 356 条
[1]   Thrombophilias as risk factors for disorders of pregnancy and fetal damage [J].
Abbate, R ;
Sofi, F ;
Gensini, F ;
Fatini, C ;
Sticchi, E ;
Fedi, S .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 (5-6) :318-321
[2]   Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. [J].
Agnelli, G ;
Prandoni, P ;
Santamaria, MG ;
Bagatella, P ;
Iorio, A ;
Bazzan, M ;
Moia, M ;
Guazzaloca, G ;
Bertoldi, A ;
Tomasi, C ;
Scannapieco, G ;
Ageno, W ;
Ascani, A ;
Villalta, S ;
Frulla, M ;
Mosena, L ;
Girolami, A ;
Vaccarino, A ;
Alatri, A ;
Palareti, G ;
Marchesi, M ;
Ambrosio, GB ;
Parisi, R ;
Doria, S ;
Steidl, L ;
Ambrosini, F ;
Silingardi, M ;
Ghirarduzzi, A ;
Iori, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :165-169
[3]   Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) study [J].
Aleksic, N ;
Ahn, C ;
Wang, YW ;
Juneja, H ;
Folsom, AR ;
Boerwinkle, E ;
Wu, KK .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (02) :348-352
[4]  
Ameziane N, 2002, THROMB HAEMOSTASIS, V88, P195
[5]   A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction [J].
Anderson, JL ;
King, GJ ;
Thomson, MJ ;
Todd, M ;
Bair, TL ;
Muhlestein, JB ;
Carlquist, JF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (05) :1206-1211
[6]   LOW HEPARIN COFACTOR-II ASSOCIATED WITH ABNORMAL CROSSED IMMUNOELECTROPHORESIS PATTERN IN 2 NORWEGIAN FAMILIES [J].
ANDERSSON, TR ;
LARSEN, ML ;
ABILDGAARD, U .
THROMBOSIS RESEARCH, 1987, 47 (02) :243-248
[7]  
Ardissino D, 1999, BLOOD, V94, P46
[8]  
Ariëns RAS, 1999, THROMB HAEMOSTASIS, V81, P203
[9]  
Arruda VR, 1997, THROMB HAEMOSTASIS, V77, P818
[10]  
Assmann G, 1996, ISRAEL J MED SCI, V32, P364